CLDN18.2 positive
|
Gastric Cancer
|
CLDN18.2 positive
|
Gastric Cancer
|
CT041 Sensitive: C2 – Inclusion Criteria
|
CT041 Sensitive: C2 – Inclusion Criteria
|
CLDN18.2 positive
|
Solid Tumor
|
CLDN18.2 positive
|
Solid Tumor
|
MIL93 Sensitive: C2 – Inclusion Criteria
|
MIL93 Sensitive: C2 – Inclusion Criteria
|
CLDN18.2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
CLDN18.2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
CT041 Sensitive: C2 – Inclusion Criteria
|
CT041 Sensitive: C2 – Inclusion Criteria
|
CLDN18.2 positive
|
Pancreatic Ductal Adenocarcinoma
|
CLDN18.2 positive
|
Pancreatic Ductal Adenocarcinoma
|
CT041 Sensitive: C3 – Early Trials
|
CT041 Sensitive: C3 – Early Trials
|
CLDN18.2 positive
|
Gastric Cancer
|
CLDN18.2 positive
|
Gastric Cancer
|
CLDN18.2-targeted CAR-T immunotherapy Sensitive: D – Preclinical
|
CLDN18.2-targeted CAR-T immunotherapy Sensitive: D – Preclinical
|
CLDN18.2 positive
|
Pancreatic Cancer
|
CLDN18.2 positive
|
Pancreatic Cancer
|
CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical
|
CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical
|